NICE Approves SpaceOAR Hydrogel Use in UK

NICE Approves SpaceOAR Hydrogel Use in UK
The National Institute for Health and Care Excellence (NICE) in the U.K. has issued a guidance for prostate cancer care that supports the use of SpaceOAR hydrogel as a protective barrier to reduce the risk of radiation damage to healthy tissues and other organs during radiation therapy. NICE’s Interventional Procedure Guidance (IPG) now allows U.K. radiation oncologists and urologists to offer patients the option of using a hydrogel spacer like SpaceOAR to reduce the risk of radiotherapy-related side effects, including incontinence, loss of sexual function, and rectal dysfunction. SpaceOAR hydrogel was developed by Augmenix to position the rectum wall away from the prostate during radiotherapy. By creating this temporary space, the hydrogel reduces the amount of radiation that reaches the rectum, minimizing its potentially damaging effects. SpaceOAR hydrogel is injected in its liquid form into the space between the prostate and the rectum. It turns into a soft, solid form that pushes the prostate and the rectum apart. The spacer is stable for three months, after which it returns to liquid form and is absorbed by the body. “We now have extensive clinical data showing that SpaceOAR hydrogel helps to significantly reduce the risk of rectal and urinary toxicities and loss of sexual function associated with radiation therapy for men with prostate cancer,” John Pedersen, president and CEO of Augmenix, said in a press release
Subscribe or to access all post and page content.